(S038) Treatment of Gastric Marginal Zone Lymphoma Utilizing a Magnetic Resonance Imaging–Guided Radiation Therapy (MRIgRT) System: Evaluation of Interfractional Target Volume Changes

News
Article
OncologyOncology Vol 30 No 4_Suppl_1
Volume 30
Issue 4_Suppl_1

This analysis demonstrates that significant interfractional target variation exists in the treatment of GMZL; this variation could lead to difficulties in target localization and/or reproducibility of treatment. MRIgRT is a promising method to evaluate and allow for adaptation to these variations.

Anupama Chundury, MD, Benjamin W. Fischer-Valuck, MD, Olga Green, PhD, Harold Li, PhD, Sasa Mutic, PhD, Maria Thomas, MD, PhD, Jiayi Huang, MD; Washington University School of Medicine

BACKGROUND: Definitive radiation therapy (RT) is the current therapeutic mainstay for Helicobacter pylori–negative or refractory localized gastric marginal zone lymphoma (GMZL). The purpose of this study was to evaluate interfractional target variation in patients undergoing definitive RT for GMZL utilizing a novel onboard magnetic resonance imaging–guided radiation therapy (MRIgRT) system.

METHODS: Five patients with GMZL were treated with definitive RT using MRIgRT. The prescription dose was 30 Gy delivered in 20 fractions of 1.5-Gy daily. Preceding initiation of treatment, patients underwent a treatment planning CT simulation and an MR simulation to delineate the clinical target volume (CTV), defined as the entire stomach. Prior to delivery of each RT fraction, a daily onboard pretreatment volumetric MRI (dMRI) was acquired for target localization. CTVs were retrospectively recontoured on the acquired MRIs, and volumes were analyzed using the treatment planning system.

RESULTS: One hundred dMRIs were evaluated. Mean daily CTV (dCTV) was 267.4 cc (standard deviation [SD], 144.3 cc). Minimum dCTV was 134.9 cc, while maximum dCTV was 864.8 cc. When compared with the planning CTV (as delineated on MR simulation), mean decrease in dCTV over the course of a full treatment was 256.1 cc (SD, 188.3 cc). The mean decrease in dCTV volume percentage was 46.5% (SD, 15%). Ninety-one of the 100 dCTVs had > 20% volume change when compared with the planning CTV; for 3 patients (60%), every dCTV percent change was greater than 20%. Finally, two patients (40%) required resimulation and replanning due to clinically relevant tumor regression or noncompliance to pretreatment eating instructions.

CONCLUSIONS: This analysis demonstrates that significant interfractional target variation exists in the treatment of GMZL; this variation could lead to difficulties in target localization and/or reproducibility of treatment. MRIgRT is a promising method to evaluate and allow for adaptation to these variations.

Proceedings of the 98th Annual Meeting of the American Radium Society -americanradiumsociety.org

Articles in this issue

(S002) A 15-Year Review of Radiation Therapy for Keloids at Two Institutions
(S003) Single-Fraction Radiation Therapy for the Treatment of Multiple Myeloma Bony Metastases Provides Pain Control and Decreases Time to Chemotherapy
(S001) Prognostic Value of Pretreatment Serum Inflammatory Markers in Patients Receiving Radiation Therapy for Oropharyngeal Cancer
(S004) Trend in Second Malignancy Risk for Head and Neck Cancer With Increased Utilization of IMRT: Analysis of SEER Database
(S005) Comparison of Legal Needs of a Group of Patients With Cancer: Economic and Geographic Factors
(S006) Mission Improvement: Lessons From Initiating a Resident-Led Quality Improvement Project on Smoking Cessation at a County Hospital
(S007) Results of a Phase II Trial Using Cetuximab Plus Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
(S008) The Effect of Simulation and Treatment Delays for Patients With Oropharyngeal Cancer Receiving Definitive Radiation Therapy in the Era of Risk Stratification Using Smoking and Human Papilloma Virus Status
(S009) Intensity-Modulated Radiation Therapy With Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on Three-Year Toxicity
(S011) Comparative Study Between Ileal Conduit and Indiana Pouch After Cystectomy for Patients With Carcinoma of Urinary Bladder
(S010) Computed Tomography–Assessed Measures of Bone Mineral Density and Muscle Mass as Predictors of Survival in Men With Prostate Cancer
(S012) Quantitative Imaging to Evaluate the Malignant Potential of Pancreatic Cysts
(S013) Spine Stereotactic Radiosurgery With Concurrent Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
(S014) The Impact of Radiation Therapy on Survival in Surgically Resected, High-Risk Patients With Ampullary Adenocarcinoma: A Population-Based Analysis
(S016) The Impact of Stereotactic Body Radiation Therapy on Overall Survival in Patients With Locally Advanced Pancreatic Cancer
Related Videos
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
There is no absolute age cutoff where CAR T cells are contraindicated for those with large B-cell lymphoma, says David L. Porter, MD.
David L. Porter, MD, emphasizes referring patients with large B-cell lymphoma early for CAR T-cell therapy consultation.
It may be applicable to administer CAR T-cell therapy to patients with large B-cell lymphoma in a community or outpatient setting.
Related Content